A watan Fabrairun 2010, Cibiyar Abincin da Drug (FDA) ta ba da ƙarin bayani game da magungunan ƙwayar ƙwayar ƙwayoyi waɗanda suka ƙunshi beta-agonists mai tsawo (LABAs), irin su Advair and Symbicort. LABAs sun kasance a Amurka tun daga tsakiyar shekarun 1990 don zama mai kula da maganin fuka. A sakamakon binciken da ake nunawa game da yin amfani da LABA da kuma ciwo da cututtukan fuka (ciki har da mutuwa daga asma), FDA ta bada shawara game da amfani da LABAs don maganin fuka har sai da dole.
Maimakon amfani da magungunan asibiti dauke da LABAs, FDA ta bada shawarar yin amfani da wasu magunguna, da farko a hayar corticosteroids , a matsayin magungunan maganin fuka. Sauran wasu sun hada da masu damun leukotriene kamar montelukast (Singulair) , omalizumab (Xolair) da theophylline. Magungunan ƙwararrun fuka da ke dauke da LABAs, ciki har da Advair, ya kamata a yi amfani dashi ga mutanen da basu sarrafawa tare da wasu magunguna kamar yadda aka ambata a sama ba, ko kuma tare da haɗari na tarin fuka da dama waɗanda ke buƙatar yin ziyara a gaggawa, asibiti ko kuma yin amfani da maganganun maganganu ko maganin corticosteroids don sarrafawa.
A matsayin likitan ƙwararru, inji sabuwar FDA ta gargadi. Babu sabon bayanai don tallafawa irin wannan gargadi tun lokacin da aka ba da Gargaɗi na Black Box da aka ba wa magungunan LABA. FDA tana magana ne da bincike biyu da ya nuna cewa LABAs na iya kara yawan bayyanar cututtukan fuka, ciki har da mutuwar fuka. Shawarar biyu da aka yi a cikin tambayoyin sun hada da Salmeterol Multicenter Asthma Research Trial (SMART) da Nazarin Harkokin Gano Hannu (SNS).
An gudanar da SMART a shekara ta 1996, tare da salmeterol (LABA) da aka ba wa mutane fiye da 13,000 da ciwon sukari. Wasu daga cikin wadannan mutane suna shan magungunan maganin fuka; wasu suna amfani salmeterol ne kawai a kowace rana. Yayin da aka gano salmeterol ya zama cikakkiyar lafiya, ya kasance yana haifar da karin hare-haren tarin fuka, da asibiti da kuma mutuwar fuka a cikin jama'ar Amurka.
Lokacin da aka yi nazari sosai a cikin wadanda suka halarci binciken na SMART, an gano cewa suna da ciwon fuka mai tsanani a matsayin rukuni, duk da haka basu iya yin amfani da maganin ƙwaƙwalwar ƙwayar cututtuka domin kula da asibinsu. Lokacin da aka gwada wa] annan jama'ar {asar Amirka, da suke amfani da maganin sanyi, wanda aka bai wa salmeterol, ba su da} ara yawan matsalolin da ake amfani da su.
Nazarin SNS yayi la'akari da sakamakon sau biyu na yau da kullum na LABA Serevent (salmeterol) zuwa salbutamol sau hudu a cikin fuka-fuki na fuka-fuka a sama da mutane 25,000 tare da asma. Duk da yake akwai ƙananan ƙananan cututtukan fuka a cikin salmeterol, wannan shine mafi kusantar dalili ne kawai saboda rashin yiwuwar kuma ba a waje da adadin yawan mutuwar mutane a cikin wannan yawan ba tare da fuka mai tsanani. An wallafa wannan binciken a 1993, tare da sakamakon da aka samu ga FDA kafin a shigar da LABA don amfani a Amurka.
LABAs sune maganin da ake amfani dasu don maganin fuka a cikin shekaru 15 ko fiye a Amurka. Duk da nazarin da aka yi a sama da kuma batun da FDA ta damu da shi, yawan mutuwar ƙwayoyin asiri ya kasance a kan raguwar shekaru 10 ko fiye.
Ya kamata ku dauki magani na asibiti wanda ya ƙunshi LABA, irin su Advair or Symbicort? Sai dai kai da likitanka kawai zasu iya yin hakan. Duk da haka, idan kuna shan LABA, yana da kyau a ganin likitan ku don tattauna hadarin da wadatar waɗannan magunguna. Yana da mahimmanci kada ku daina shan duk likita, ciki har da LABAs, kafin tattaunawa tare da likitanku.
Ƙara koyo game da haɗari da kuma amfani da amfani da Advair .
> Sources:
> Nelson HS, Weiss ST, Bleeker ER, et al. Salmeterol Multicenter Asthma Research Trial. Chest. 2006; 129: 15-26.
> Nelson HS. Magoya bayan Beta-Agonists a cikin Asthma Adult: Shaida cewa wadannan kwayoyi suna Safe. Farfesa na asibiti na asibiti. 2006; 15: 271-77.
> Castle W, Fuller R, Hall J, Palmer J. Jana'izar Nazarin Harkokin Kulawa: Ƙarƙashin Salmeterol tare da Salbutamol a Asthmatic Marasa lafiya wanda ke Bukata Bronchodilator Jiyya kullum. BMJ. 1993; 306: 1034-7.